Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients.

Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Miccoli P, Grasso L, Pinchera A, Vitti P.

Endocr Relat Cancer. 2010 Feb 18;17(1):231-9. doi: 10.1677/ERC-09-0251. Print 2010 Mar.

2.

Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine.

Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, Scutari M, Basolo F, Di Coscio G, Grasso L, Pinchera A, Vitti P.

Endocr Relat Cancer. 2011 Jul 1;18(4):429-37. doi: 10.1530/ERC-11-002. Print 2011 Aug.

3.

Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role.

Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, Pinchera A, Vitti P.

Endocr Relat Cancer. 2009 Dec;16(4):1251-60. doi: 10.1677/ERC-09-0036. Epub 2009 Jun 15.

4.

Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH.

Persani L, Preziati D, Matthews CH, Sartorio A, Chatterjee VK, Beck-Peccoz P.

Clin Endocrinol (Oxf). 1997 Aug;47(2):207-14.

PMID:
9302396
5.

Iodized salt improves the effectiveness of L-thyroxine therapy after surgery for nontoxic goitre: a prospective and randomized study.

Carella C, Mazziotti G, Rotondi M, Del Buono A, Zito G, Sorvillo F, Manganella G, Santini L, Amato G.

Clin Endocrinol (Oxf). 2002 Oct;57(4):507-13.

PMID:
12354133
6.

Comparison between TRH-stimulated TSH and basal TSH measurement by a commercial immunoradiometric assay in the management of thyroid disease.

De Rosa G, Testa A, Giacomini D, Carrozza C, Maussier ML, Valenza V, D'Errico GF.

Q J Nucl Med. 1996 Jun;40(2):182-7.

PMID:
8909104
7.

Are endogenously lower serum thyroid hormones new predictors for thyroid malignancy in addition to higher serum thyrotropin?

Gul K, Ozdemir D, Dirikoc A, Oguz A, Tuzun D, Baser H, Ersoy R, Cakir B.

Endocrine. 2010 Apr;37(2):253-60. doi: 10.1007/s12020-010-9316-6. Epub 2010 Mar 13.

PMID:
20960260
8.

Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size.

Baldini M, Gallazzi M, Orsatti A, Fossati S, Leonardi P, Cantalamessa L.

J Intern Med. 2002 May;251(5):407-14.

9.

[Incidental differentiated thyroid carcinoma is less prevalent in Graves' disease than in multinodular goiter].

Pascual Corrales E, Príncipe RM, Laguna Muro S, Martínez Regueira F, Alcalde Navarrete JM, Guillén Grima F, Galofré JC.

Endocrinol Nutr. 2012 Mar;59(3):169-73. doi: 10.1016/j.endonu.2011.12.004. Epub 2012 Feb 9. Spanish.

PMID:
22325789
10.

Solitary nodular disease and multinodular goiter: a retrospective study on suppressive versus replacement levothyroxine therapy.

Paggi A, Persegani-Trimarchi C, Russo P, Mastropasqua M, Mosetti MA, Losi T, Leri O.

Endocr Res. 1999 May;25(2):229-38.

PMID:
10382684
11.

[Correlation between serum thyroglobulin and thyroid stimulating hormone in populations with non-toxic goiter].

Hu FN, Jin Y, Teng WP, Yang F, Teng XC, Gao TS, Wang WB, Shi XG, Tao CM.

Zhonghua Yi Xue Za Zhi. 2003 Jun 10;83(11):936-9. Chinese.

PMID:
12899791
12.

Papillary thyroid cancer, although strongly associated with lymphocytic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases.

Fiore E, Rago T, Scutari M, Ugolini C, Proietti A, Di Coscio G, Provenzale MA, Berti P, Grasso L, Mariotti S, Pinchera A, Vitti P.

J Endocrinol Invest. 2009 Apr;32(4):344-51.

PMID:
19636204
14.

A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.

Ngan ES, Lang BH, Liu T, Shum CK, So MT, Lau DK, Leon TY, Cherny SS, Tsai SY, Lo CY, Khoo US, Tam PK, Garcia-Barceló MM.

J Natl Cancer Inst. 2009 Feb 4;101(3):162-75. doi: 10.1093/jnci/djn471. Epub 2009 Jan 27.

PMID:
19176457
15.

Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter.

Güllü S, Gürses MA, Başkal N, Uysal AR, Kamel AN, Erdoğan G.

Endocr J. 1999 Feb;46(1):221-6.

16.

The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer.

Ruchala M, Skiba A, Gurgul E, Uruski P, Wasko R, Sowinski J.

Neuro Endocrinol Lett. 2009;30(3):382-6.

PMID:
19855364
17.

[Evaluation of the treatment with L-thyroxine: lack of correspondence between objectives and results].

Negro R, Dazzi D, Pezzarossa A.

Minerva Endocrinol. 2000 Mar;25(1):11-7. Italian.

PMID:
11148845
18.

Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease.

Fiore E, Vitti P.

J Clin Endocrinol Metab. 2012 Apr;97(4):1134-45. doi: 10.1210/jc.2011-2735. Epub 2012 Jan 25.

PMID:
22278420
19.

Clinicopathological correlation of serum TSH in patients with thyroid nodule.

Mondal HP, Sen S, Sasmal S, Ghosal PK, Mukhopadhyay SK, Mukhopadhyay M.

J Indian Med Assoc. 2011 May;109(5):330, 335, 338.

PMID:
22187768
20.

Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease.

Rago T, Fiore E, Scutari M, Santini F, Di Coscio G, Romani R, Piaggi P, Ugolini C, Basolo F, Miccoli P, Pinchera A, Vitti P.

Eur J Endocrinol. 2010 Apr;162(4):763-70. doi: 10.1530/EJE-09-0895. Epub 2010 Jan 18.

Supplemental Content

Support Center